Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Philip WongLaura MasucciMarie FlorescuMarc-Emile PlourdeValerie Panet-RaymondMichel PavicScott P OwenLaurence Masson-CotéCynthia MénardBertrand RoutyMustapha TehféKristoff NelsonFrançois GuilbertOlivier BoucherSareh KeshavarziNormand BlaisDavid RobergePublished in: Neuro-oncology advances (2023)
The adverse event profile and FACT-Br assessments suggested that SRS during nivolumab was well tolerated. Upfront SRS with the initiation of anti-PD-1 prolonged the 1-year iPFS and achieved high intracranial control. This combined approach merits validation randomized studies.